

## STATUS OF PATENT APPLICATIONS BY GILEAD RELATING TO LENACAPAVIR

Serial No.	Application Number	Date of Filing	Details	PCT Number	Oppositions Raised	PGO Document
1	7740/DELNP/2015	21 August 2015	Amide Compounds For The Treatment Of HIV  (Markush compound)	PCT/US2014/019663; WO/2014/134566	<ol style="list-style-type: none"> <li>1. Certain claims are broad, vague, and unclear, lacking the necessary definitiveness.</li> <li>2. Some claims do not qualify as products or processes under Section 2(1)(j).</li> <li>3. Certain claims fail to demonstrate an inventive step as required under Section 2(1)(ja).</li> <li>4. Some claims are non-patentable under Section 3 as they consist of additional therapeutic agents without demonstrating their synergistic effects.</li> <li>5. Several claims are speculative in scope and unclear, failing to meet the sufficiency of disclosure as outlined in Section 10(4).</li> <li>6. Certain claims comprise compounds that exhibit unity of invention under Section 10(5) but exceed the scope of the independent claim.</li> </ol>	<a href="#">pdf</a>
2	IN201917006277	18 February 2019	Therapeutic Compounds Useful For The Prophylactic Or	PCT/US2017/047416 WO/2018/035359	<ol style="list-style-type: none"> <li>1. The invention demonstrates no technical advancement through the innovative synthesis of compounds</li> </ol>	<a href="#">pdf</a>

			Therapeutic Treatment Of An HIV Virus Infection  (Compound)		with enhanced therapeutic effects, non patentable under u/s 2(1)(j)  2. The claims are not fully supported by the complete specification, failing to meet the requirements of Section 10(4)(a/b/c).	
3	IN202018020805 (Divisional of IN201917006277)	18 May 2020	Therapeutic Compounds Useful For The Prophylactic Or Therapeutic Treatment Of An HIV Virus Infection  (Parenteral Formulation)	PCT/US2017/047416 WO/2018/035359	1. Lack of inventive step under Section 2(1)(ja).  2. Invention is not patentable under Sections 3(d) and 3(e).  3. The complete specification does not sufficiently and clearly describe the invention or the method by which it is to be performed.  4. Failed to disclose to the Controller the information required by Section 8	<a href="#">pdf</a>
4	IN202017007904	25 February 2020	Choline Salt Forms Of An HIV Capsid Inhibitor  (Crystalline salt and isomer forms)	PCT/US2018/000248 WO/2019/035973	1. Lack of inventive step under Section 2(1)(ja).  2. Non-patentability under Section 3(d) since the compounds are crystalline forms of a known compound.  3. Claims not supported by description as per Section 10 of the Patents Act, 1970.	<a href="#">pdf</a>
5	IN202017010006	9 March 2020	Crystalline salt and isomer forms	PCT/US2018/000172 WO/2019/035904	1. Lack of inventive step under Section 2(1)(j).  2. Claims fall under Section 3(d) since the compounds are crystalline forms of a known compound  3. Claims not supported by description	<a href="#">pdf</a>

					<p>as per Section 10 of the Patents Act, 1970.</p> <p>4. The instant application and co-pending applications relate to the same subject matter; no two applications with the same subject matter can be granted.</p>	
--	--	--	--	--	--	--